← Eichor
Condition: Metastatic Endocrine Refractory Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Metastatic Endocrine Refractory

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Phase 2 · 2 location(s) · Jochen Lorch · NCT06959641Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT03099356Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
NA · 1 location(s) · European Institute of Oncology · NCT06785077Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Phase 1/Phase 2 · 3 location(s) · National Cancer Institute (NCI) · NCT05053971CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Phase 2 · 6 location(s) · Massachusetts General Hospital · NCT05668962A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Phase 1 · 9 location(s) · Normunity AccelCo, Inc. · NCT07182149Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carc
Phase 3 · 35 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06860971TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancrea
Phase 1 · 1 location(s) · University of California, Davis · NCT07189195A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 · 18 location(s) · NiKang Therapeutics, Inc. · NCT07029399177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Radiopharm Theranostics, Ltd · NCT07189871Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Phase 3 · 40 location(s) · AstraZeneca · NCT07205822A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Diff
Phase N/A · 3 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT05994365A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 · 19 location(s) · NiKang Therapeutics, Inc. · NCT06586957Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06970353Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07229417TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 · 41 location(s) · Tizona Therapeutics, Inc · NCT04485013IDOV-Immune for Advanced Solid Tumors
Phase 1 · 5 location(s) · ViroMissile, Inc. · NCT06910657
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.